Nourish raises $100M Series C to fund AI-native metabolic health platform; Aims to treat chronic diseases with dietary changes.

Nourish, a nutrition counseling startup, has secured $100 million in Series C funding to enhance its AI-native metabolic health platform, targeting chronic disease management through dietary modifications.
The latest funding round, led by Menlo Ventures, brings Nourish’s total funding to $215 million and boosts its valuation to $1.75 billion according to sources.
The investment aims to fortify Nourish's existing network of over 10,000 registered dietitians across all 50 states, who have collectively served hundreds of thousands of patients.
This platform is designed to address chronic diseases—an enormous cost driver in U.S. healthcare—where accessible and effective treatment is lacking. Aidan Dewar, Co-Founder and CEO of Nourish, remarked, "Chronic disease is the largest cost driver in U.S. healthcare, and the system still isn't built to treat it."
The funding will accelerate investments in AI agents for both patients and providers, expand its metabolic clinic care model, and deepen partnerships with leading health plans.
Nourish’s unique combination of lifestyle modifications and responsible prescribing of brand-name, insurance-covered GLP-1s facilitates significant patient outcomes, noting an impressive 8% weight loss and a 1.3 point A1C reduction, resulting in over $2,000 annual savings per patient for health plans.
Moreover, 68% of Nourish patients remained on GLP-1 therapy at six months, compared to a 46% industry benchmark, highlighting the effectiveness of its integrated approach.

Nourish has raised $100 million in a Series C round led by Menlo Ventures, bringing its total funding to $215 million. The funds will expand its AI-native metabolic health platform aimed at treating chronic diseases through dietary interventions, enhancing care accessibility via a network of over 10,000 dietitians.